



WEEKLY EPIDEMIOLOGICAL REPORT

SRI LANKA 2025

WEEKLY EPIDEMIOLOGICAL REPORT

A publication of the Epidemiology Unit

Ministry of Health & Mass Media

231, de Saram Place, Colombo 01000, Sri Lanka

Tele: + 94 11 2695112, Fax: +94 11 2696583, E mail: epidunit@slt.net.lk

Epidemiologist: +94 11 2681548, E mail: chepid@slt.net.lk

Web: <http://www.epid.gov.lk>

Vol. 52 No. 45

01st – 07th Nov 2025

Primary Amoebic Meningitis (PAM) - Part II

*This is the second article of two in a series on
“Primary Amoebic Meningitis (PAM)”*

A few Primary amoebic encephalitis cases had been reported in Sri Lanka, and only a limited number of studies had been conducted in Sri Lanka on *Naegleria* species, mainly in the North Western province in selected water bodies. According to them, this species had been isolated from water bodies located in four Divisional Secretariat (DS) divisions in the Kurunegala district, namely Maho, Nikaweratiya, Kotawehera and Abanpola DS divisions. These were selected for the study based on the density of water bodies. Of 20 tanks, 10 were positive for *Naegleria* species. However, a study conducted from 2013 to 2018 had shown the prevalence of *Naegleria* species in the surface water and deep water were 4.48% and 3.20%, respectively. It had also revealed the prevalence of *Naegleria* species is 23.07% and *N. fowleri* in the study area was 1.92%.

This is a unicellular organism and can be isolated from soil, air and in water systems such as natural, industrial and domestic. The usual habitat of this single-celled organism is warm, fresh water environments like lakes, rivers, hot springs and untreated swimming pools. When the contaminated water is forced up the nose to the brain, the organism can enter the brain through the nasal cavity and adhere to the olfactory nerves and cross the cribriform plate, ending up in the olfactory bulb. The infection is more common in young adults and children as they have a more porous cribriform plate.

Early symptoms of the infection include headache, fever, nausea and in the later stages, the symptoms worsen rapidly. The later symptoms include neck stiffness, confusion, hallucinations, seizures and coma. However, clinically, it is difficult to differentiate from bacterial meningitis. Diagnosis is made by examination of cerebrospinal fluid (CSF) wet mounts for motile trophozoites. PAM generally results in death within 3- 7 days of symptom onset.





Figure 4: Life cycle of *N. fowleri*



1. Primary Amoebic Meningitis (PAM) - Part II
2. Summary of selected notifiable diseases reported (25th – 31st Oct 2025)
3. Surveillance of vaccine preventable diseases & AFP (25th – 31st Oct 2025)

1

3

4

Amphotericin B is the most widely used drug for treating *N. fowleri* infection, generally administered as a 14-day course. Aazithromycin and Miltefosine have presented limited success. However, existing information on potential therapies is largely derived from a handful of case reports and experimental studies in laboratory and animal models. Unfortunately, the rarity of cases and the swift progression of the disease severely limit the feasibility of conducting clinical trials to evaluate the effectiveness and safety of these treatment options.

Prevention

Proper chlorination and disinfection of pools water supply is an essential preventive strategy. Free chlorine levels of at least 2.0 mg/L in water storage tanks can effectively eliminate the pathogen. Additionally, boiled or sterilised water should always be used for rinsing, flushing, or irrigating nasal passages to prevent infection. Maintaining a high index of suspicion by healthcare professionals may help early diagnosis and timely initiation of multi-drug therapy. Strong efforts are required to advance the healthcare system capacity, particularly in developing countries, to facilitate early diagnosis and appropriate treatment to enhance the prognosis of PAM cases.

Future outbreaks of *N. fowleri* can also be averted by adhering to cleaning regulations for freshwater sources, conducting routine testing, and repairing water pipelines, especially in the warmer months. We recommend broader surveillance worldwide, the establishment of a genetic data bank, the development of prompt diagnostic techniques, exploration of potential therapeutic options, and development of vaccines to prevent *N. fowleri* outbreaks.

Compiled by:

Dr Niluka Gunathilaka
Consultant Community Physician
Kurunegala

References:

- Guemez, A., & Garcia, E. Primary Amoebic Meningoencephalitis by *Naegleria fowleri*: Pathogenesis and Treatments. *Biomolecules*, 11 (9) (2021), [10.3390/biom11091320](https://doi.org/10.3390/biom11091320)
- Alanazi, A., Younas, S., Ejaz, H., Alruwaili, M., Alruwaili, Y., Mazhari, B. B. Z., Atif, M., & Junaid, K. (2025). Advancing the understanding of *Naegleria fowleri*: Global epidemiology, phylogenetic analysis, and strategies to combat a deadly pathogen. *Journal of Infection and Public Health*, 18(4), 102690. <https://doi.org/10.1016/j.jiph.2025.102690>
- Shakoor, S. Beg, M.A., Mahmood, F., Bandea, R., Sriram, R., Noman, F. et al. Primary amoebic meningoencephalitis caused by *Naegleria fowleri*, Karachi, Pakistan. *Emerg Infect Dis*, 17 (2) (2011), pp. 258-261, [10.3201/eid1702.100442](https://doi.org/10.3201/eid1702.100442)
- Gunarathna1, J.A.N.S., Iddawela, D., Wickramasinghe, S., A preliminary study on *Naegleria* species in water bodies of Kurunegala district, Sri Lanka, *Sri Lankan Journal of Infectious Diseases* 2018 Vol.8(2)74-83.<https://sljid.sljol.info/articles/10.4038/sljid.v8i2.8216>
- Gunarathna N, Amarasinghe A, Wijesundara S, Iddawela D, Wickramasinghe S (2021) Isolation, molecular characterization and phylogeny of *Naegleria* species in water bodies of North-Western Province, Sri Lanka. *PLoS ONE* 16(3): e0248510. <https://doi.org/10.1371/journal.pone.0248510>
- Anser, H., & Hasan, A., A review on global distribution of primary amoebic meningoencephalitis (PAM) caused by *Naegleria fowleri*-the brain eating amoeba. *RADS J Pharm Pharm Sci*, 6 (1) (2018), pp. 95-99
- Heggie, T.W. & Kupper, T., Surviving *Naegleria fowleri* infections: A successful case report and novel therapeutic approach. *Travel Med Infect Dis*, 16 (2017), pp. 49-51, [10.1016/j.tmaid.2016.12.005](https://doi.org/10.1016/j.tmaid.2016.12.005)
- Yoder, J.S., Eddy, B.A., Visvesvara, G.S., Capewell, L., Beach, M.J., The epidemiology of primary amoebic meningoencephalitis in the USA, 1962-2008. *Epidemiol Infect*, 138 (7) (2010), pp. 968-975, [10.1017/S0950268809991014](https://doi.org/10.1017/S0950268809991014)
- Visvesvara, G.S., Moura, H., Schuster F.L. Pathogenic and opportunistic free-living amoebae: *Acanthamoeba* spp., *Balamuthia mandrillaris*, *Naegleria fowleri*, and *Sappinia diploidea*. *FEMS Immunol Med Microbiol*, 50 (1) (2007), pp. 1-26, [10.1111/j.1574-695X.2007.00232.x](https://doi.org/10.1111/j.1574-695X.2007.00232.x)
- Grace, E., Asbill, S., & Virga, K. *Naegleria fowleri*: pathogenesis, diagnosis, and treatment options. *Antimicrob Agents Chemother*, 59 (11) (2015), pp. 6677-6681, [10.1128/AAC.01293-15](https://doi.org/10.1128/AAC.01293-15)
- Visvesvara G.S., Infections with free-living amoebae. *Handb Clin Neurol*, 114 (2013), pp. 153-168, [10.1016/b978-0-444-53490-3.00010-8](https://doi.org/10.1016/b978-0-444-53490-3.00010-8)
- Miller, H.C, Wylie, J., Dejean, G., Kaksonen, A.H., Sutton, D., Braun, K., et al. Reduced Efficiency of Chlorine Disinfection of *Naegleria fowleri* in a Drinking Water Distribution Biofilm. *Environ Sci Technol*, 49 (18) (2015), pp. 11125-11131. <https://doi.org/10.1021/acs.est.5b02947>
- Jahangeer,M., Mahmood,Z., Mu-nir,N., Waraich,U.E., Tahir,I.M., Akram,M. et al. *Naegleria fowleri*: Sources of infection, pathophysiology, diagnosis, and management; a review. *Clin Exp Pharm Physiol*, 47 (2) (2020), pp. 199-212, [10.1111/1440-1681.13192](https://doi.org/10.1111/1440-1681.13192)
- Shrestha GS, Parajuli NP, Shrestha PS, Acharya SP, Hamal R, Gajurel B, Khanal K, Marhatta MN. Primary amoebic meningoencephalitis. *J Neurosci Rural Pract*. 2015 Apr-Jun;6(2):284-6. doi: 10.4103/0976-3147.153244. PMID: 25883507; PMCID: PMC4387838.

Table 1: Selected notifiable diseases reported by Medical Officers of Health 25th-31st Oct 2025 (44th Week)

RDHS	Dengue Fever		Dysentery		Encephalitis		En. Fever		F. Poisoning		Leptospirosis		Typhus F.		Viral Hep.		H. Rabies		Chickenpox		Meningitis		Leishmania-		Tuberculosis		WRCD			
	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B	C**					
Colombo	153	9782	3	32	1	17	1	15	0	36	13	390	0	5	0	32	0	0	21	511	2	67	1	5	40	1775	89	100		
Gampaha	112	6322	2	48	1	33	0	4	0	151	36	732	0	11	1	18	0	0	18	756	15	163	1	41	27	1019	93	100		
Kalutara	32	2128	2	38	0	6	0	20	6	99	11	562	0	3	0	7	0	0	21	774	1	46	0	3	16	505	94	95		
Kandy	58	3820	1	46	0	3	0	8	1	56	5	268	0	48	0	10	0	0	18	554	1	23	3	68	17	560	74	100		
Matale	22	1124	0	25	0	3	0	2	0	86	0	226	0	6	0	9	0	0	3	128	0	9	20	313	1	130	77	100		
Nuwara Eliya	5	309	2	78	0	6	0	7	2	76	3	173	1	56	0	9	0	0	11	295	1	36	0	0	5	251	90	100		
Galle	30	1860	1	55	1	9	1	8	3	95	18	761	1	78	1	13	0	2	18	704	1	151	0	3	8	453	100	100		
Hambantota	14	800	2	41	0	7	0	2	28	37	3	333	0	30	0	16	0	0	19	291	3	28	4	308	1	127	100	100		
Matara	23	1381	1	17	0	3	0	1	4	25	7	422	0	15	2	21	0	1	10	397	2	47	2	103	1	153	94	100		
Jaffna	55	1115	1	84	0	3	0	18	0	46	3	142	15	462	0	3	0	2	3	304	4	31	0	0	3	183	100	93		
Kilinochchi	2	89	0	14	0	1	0	4	0	7	0	64	0	12	0	1	0	0	0	10	0	10	0	1	0	2	1	43	100	100
Mannar	7	155	0	6	0	0	0	1	0	3	0	31	0	18	0	2	0	0	0	19	0	15	0	9	1	44	100	100		
Vavuniya	1	80	0	10	0	0	0	1	2	40	1	83	0	10	0	0	0	0	0	47	0	21	1	20	1	55	100	100		
Mullaitivu	1	55	1	7	0	0	0	1	0	26	2	55	0	10	0	1	0	0	0	32	0	8	0	4	2	31	100	100		
Batticaloa	19	1653	0	130	1	16	0	4	1	202	2	110	0	2	1	27	0	0	4	175	0	33	0	1	2	123	86	100		
Ampara	5	224	0	54	0	11	0	3	2	43	8	210	0	3	0	13	0	1	10	216	5	52	1	24	2	56	86	100		
Trincomalee	15	951	1	41	0	4	0	2	0	78	3	128	0	9	1	6	0	1	5	125	0	12	0	9	1	117	100	100		
Kurunegala	15	1432	0	43	0	18	0	2	3	63	14	648	1	26	1	8	0	1	13	804	7	157	16	550	13	328	86	100		
Puttalam	11	568	1	34	0	3	0	0	0	15	13	273	0	36	0	4	0	1	0	143	4	98	0	29	3	177	100	100		
Anuradhapura	9	492	1	33	0	6	0	3	2	43	5	332	0	25	0	12	0	2	1	308	1	60	24	699	4	278	73	100		
Polonnaruwa	3	316	0	16	0	6	0	1	0	142	1	248	0	1	0	25	0	0	4	187	0	23	11	416	1	83	88	90		
Badulla	7	717	3	35	2	14	1	4	0	11	6	277	4	38	4	76	0	0	12	373	1	77	1	65	4	252	100	100		
Monaragala	16	760	0	30	0	5	0	1	0	19	7	482	0	39	2	59	0	0	28	224	2	53	7	213	7	133	91	100		
Ratnapura	57	4304	1	100	0	10	0	4	0	72	25	1390	2	32	0	18	0	2	5	410	2	101	2	203	8	350	82	100		
Kegalle	19	1309	0	55	0	13	0	10	6	42	15	711	0	15	0	20	0	0	25	826	1	119	2	31	9	262	100	100		
Kalmunai	10	374	0	45	0	7	0	0	29	52	0	106	0	2	0	5	0	1	14	235	0	54	0	1	6	130	77	100		
SRILANKA	701	42120	23	1117	6	204	3	126	89	1565	201	9157	24	992	13	415	0	14	263	8848	53	1485	96	3120	184	7618	92	99		

Source: Weekly Returns of Communicable Diseases (esurveillance.epid.gov.lk). T=Timeliness refers to returns received on or before 31st Oct, 2025 Total number of reporting units 360 Number of reporting units data provided for the current week 359. C**=Completeness. A = Cases reported during the current week. B = Cumulative cases for the year.

Table 2: Vaccine-Preventable Diseases & AFP

25th – 31st Oct 2025 (44th Week)

Disease	No. of Cases by Province										Number of cases during current week in 2025	Number of cases during same week in 2024	Total number of cases to date in 2025	Total number of cases to date in 2024	Difference between the number of cases to date in 2025 & 2024
	W	C	S	N	E	NW	NC	U	Sab						
AFP*	00	00	00	00	00	00	00	00	00	00	03	50	63	-20.6%	
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Mumps	01	02	01	00	00	00	00	00	00	04	06	215	236	-8.9 %	
Measles	00	00	00	00	00	00	00	00	00	00	02	01	289	-99.6%	
Rubella	00	00	00	00	00	00	00	00	00	00	00	04	02	-100%	
CRS**	00	00	00	00	00	00	00	00	00	00	00	01	00	0 %	
Tetanus	02	00	00	00	00	00	00	00	00	02	00	11	05	120 %	
Neonatal Tetanus	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Japanese Encephalitis	00	00	00	00	00	00	00	00	00	00	00	04	09	-55.5 %	
Whooping Cough	00	00	00	00	00	00	00	00	00	00	00	22	56	-60.7 %	

Key to Table 1 & 2

Provinces: W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.

RDHS Divisions: CB: Colombo, GM: Gampaha, KL: Kalutara, KD: Kandy, ML: Matale, NE: Nuwara Eliya, GL: Galle, HB: Hambantota, MT: Matara, JF: Jaffna, KN: Killinochchi, MN: Mannar, VA: Vavuniya, MU: Mullaitivu, BT: Batticaloa, AM: Ampara, TR: Trincomalee, KM: Kalpitiya, KR: Kurunegala, PU: Puttalam, AP: Anuradhapura, PO: Polonnaruwa, BD: Badulla, MO: Moneragala, RP: Ratnapura, KG: Kegalle.

Data Sources:

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps., Rubella, CRS,

Special Surveillance: AFP* (Acute Flaccid Paralysis), Japanese Encephalitis

CRS** =Congenital Rubella Syndrome

NA = Not Available

Take prophylaxis medications for leptospirosis during the paddy cultivation and harvesting seasons.

It is provided free by the MOH office / Public Health Inspectors.

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk. Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication

ON STATE SERVICE

Dr. Palitha Karunapema
CHIEF EPIDEMIOLOGIST
EPIDEMIOLOGY UNIT
231, DE SARAM PLACE
COLOMBO 10